Business Description
BriaCell Therapeutics Corp
NAICS : 325414
SIC : 3741
ISIN : CA10778Y1043
Share Class Description:
TSX:BCT: Ordinary Shares - NewDescription
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.39 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 10 | |||||
| 3-Year EPS without NRI Growth Rate | -12 | |||||
| 3-Year FCF Growth Rate | 1.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 31.74 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 22.2 | |||||
| 9-Day RSI | 28.74 | |||||
| 14-Day RSI | 33.88 | |||||
| 6-1 Month Momentum % | 12.5 | |||||
| 12-1 Month Momentum % | -74.54 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.65 | |||||
| Quick Ratio | 1.65 | |||||
| Cash Ratio | 1.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.2 | |||||
| Shareholder Yield % | -61.54 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -154.25 | |||||
| ROIC % | -1348.48 | |||||
| 3-Year ROIIC % | -1352.34 | |||||
| ROC (Joel Greenblatt) % | -1981.45 | |||||
| ROCE % | -513.1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.83 | |||||
| Price-to-Tangible-Book | 3.93 | |||||
| EV-to-EBIT | -0.42 | |||||
| EV-to-Forward-EBIT | -0.41 | |||||
| EV-to-EBITDA | -0.43 | |||||
| EV-to-FCF | -0.54 | |||||
| Price-to-Net-Current-Asset-Value | 8.43 | |||||
| Earnings Yield (Greenblatt) % | -238.1 | |||||
| FCF Yield % | -122.66 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BriaCell Therapeutics Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | |||
| EPS (TTM) (C$) | -1.202 | ||
| Beta | 2.67 | ||
| Volatility % | 94.58 | ||
| 14-Day RSI | 33.88 | ||
| 14-Day ATR (C$) | 0.113048 | ||
| 20-Day SMA (C$) | 0.777 | ||
| 12-1 Month Momentum % | -74.54 | ||
| 52-Week Range (C$) | 0.56 - 6.18 | ||
| Shares Outstanding (Mil) | 44.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BriaCell Therapeutics Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BriaCell Therapeutics Corp Stock Events
| Event | Date | Price(C$) | ||
|---|---|---|---|---|
| No Event Data | ||||
BriaCell Therapeutics Corp Frequently Asked Questions
What is BriaCell Therapeutics Corp(TSX:BCT)'s stock price today?
The current price of TSX:BCT is C$0.59. The 52 week high of TSX:BCT is C$6.18 and 52 week low is C$0.56.
When is next earnings date of BriaCell Therapeutics Corp(TSX:BCT)?
The next earnings date of BriaCell Therapeutics Corp(TSX:BCT) is 2025-03-18 Est..
Does BriaCell Therapeutics Corp(TSX:BCT) pay dividends? If so, how much?
BriaCell Therapeutics Corp(TSX:BCT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers